Corporate Governance

Committee Structures & Overview

Daniel Bürgin

*1963 in Switzerland, he joined T3 BioScience as their CEO in early 2016. His background is in economics with degrees from the Federal Business School of Commerce and a Swiss Federal Degree in Organization & Project Management. Prior to joining T3, Burgin spent 30+ years in the financial industry, eventually building his own business in Tokyo that was acquired by the New York Stock Exchange Group in 2011, for whom he continued to be the Executive Director, responsible for their Asia Pacific commercial technology division.

Chief Executive Officer

CEO, Investor & Member of the Board of Directors. He joined the Board in early 2016, when accepting his role as T3's CEO. Daniel Bürgin has a Swiss federal degree in economics and 30 years experience in capital markets. Prior to T3 he was founder and CEO of his own startup, which he successfully sold to the New York Stock Exchange Group in 2011, for whom he was managing their APAC business as Senior Vice President.

Ching-Hong Yang, Ph.D.

Founder, Chief Scientific Officer

Born in 1958 in Taiwan and now a US citizen. Dr. Ching-Hong Yang is Professor in the Department of Biological Sciences at University of Wisconsin Milwaukee. Dr. Yang is an active contributor of scientific publications and recipient of multiple grants from US governmental agencies (United States Department of Agriculture & the US National Science Foundation), universities and the private sector.

Ching-Hong has a Ph.D. in Plant Pathology from the University of California (1993) and is the founder of T3 BioScience, LLC and serves as the company's Chief Scientific Officer.

Dr. Xin Chen, Ph.D., Board Director


PhD - Investor & Member of the Board of Directors since T3's legal inception in 2013. Dr. Chen has a PhD in in Organic Chemistry. Currently, Xin Chen is the CEO of his own biotech startup and a professor at the Department of Pharmaceutical Engineering and Life Science, Changzhou University, China. He contributes to T3's science strategy and initiatives and is actively involved through his startup in the R&D for the synthetic compounds for medical use. He contributes to T3's science R&D strategy.

David Hong


Investor & Member of the Board of Directors since T3's legal inception in 2013. David Hong has a Bachelor of Engineering Science and is a highly successful entrepreneur running his own successful global businesses out of Hong Kong. He has been in the manufacturing field of metalwork for 35 years and specializes in the distribution channels of global chain stores. Currently, David is the CEO in Winners Group and Active Tools Group, Hong Kong. He contributes to T3's business strategy and financial planning.

Johnny Huang


Investor & Member of the Board of Directors since August 2017. Johnny Huang has a PhD in Engineering Management from University of Missouri-Rolla, USA. Johnny Huang has successfully built his own business, Brogent Technologies, including its IPO on Taiwan's stock exchange. Johnny Huang continues to be Brogent's Chairman and is also a professor in the Department of Engineering & Management of Advanced Technology at the Chang Jung Christian University, Taiwan. He contributes to T3's business strategy, PR and Investor Relations.

David Yang, Board Director


Investor & Member of the Board of Directors since August 2017. David Yang holds a Bachelor Degree from the University of California, Irvine and is the Executive Director for 360T, the FX division of Deutsche Börse Group. Prior to Deutsche Börse, he was an executive sales manager for the New York Stock Exchange Group for Japan and Korea. David has 10 years experience as a sales executive responsible for Asian financial products on behalf of his companies. He will contribute to T3's sales strategy, its commercial business models and business development efforts.

Dr. Wen-Pin Su, MD., Ph.D.

Medical Advisor

Associate Professor at the National Cheng Kung University Hospital (Taiwan) is a medical doctor and a Principal Investigator who studies DNA repair and anti-oxidant stress in oncology. He received M.D. degree from National Taiwan University in 1999 and Ph.D. at National Cheng Kung University in 2012. He completed his residency training at Department of Internal Medicine and Department of Oncology, Medical College Hospital, National Taiwan University. In 2007, he joined the Department of Medicine, School of Medicine, National Cheng Kung University. He is now an attending physician and Associate Professor that supervise a team of medical students, residents, and fellows at National Cheng Kung University.

Dr. Gregory Downs

Medical Advisor

Dr. Gregory Downs - is an anesthesiologist in Milwaukee, Wisconsin. He received his medical degree from Medical College of Wisconsin in 1985 and has been in practice for more than 20 years. He completed his residency in 1989 at Case Western Reserve University School of Medicine and then completed the fellowship program at University of California Irvine Medical Center. Dr. Down's specialties include general anesthesiology, critical care medicine, and obstetrical anesthesiology. Dr. Downs is board certified in Anesthesiology and is affiliated with Columbia St. Mary's hospital, Mequon, Wisconsin.

Douglas Stafford, Ph.D.

Scientific Advisor, Clinical Science

Director at the Milwaukee Institute for Drug Discovery joined UWM in 2011. Douglas has over 20 years of experience in biomedical product companies with senior management responsibilities in research and development, manufacturing operations, regulatory and clinical affairs, organizational development, patent licensing, and finance. He is inventor on over a dozen biomedical patents, has formed numerous public and private research collaborations, and participated in the development of several entrepreneurial businesses.

Dr George Sudin PhD

Agricultural Advisor

Dr. George Sudin - received a Ph.D. in Plant Pathology from Oklahoma State University in 1994. He is currently a Professor in the Department of Plant, Soil, and Microbial Sciences at Michigan State University.

George is an internationally recognized plant bacteriologist whose major research focus is on fire blight disease and the causal bacterial pathogen Erwinia amylovora. He also leads a widely recognized extension tree fruit program covering diseases of pome and stone fruits and conducts research in the detection of fungicide resistance and characterization of resistance mechanisms in pathogens such as Venturia inaequalis and Blumeriella jaapii.

T3's management has concluded that Dr. Sundin will be sufficient for agriculture, as his advise is complemented by the retainer of specialist Dr. Mark Trimmer of Dunham Trimmer, who has more than 30 years of experience in agricultural research, product development, EPA registration and technology licensing in the crop protection industry.

Members Executive
Management Team
Board Corporate
Governance Team
Comittee for
Committee all staff
(excl legal directors)
Medical Scientific
Advisory Team
Agricultural Scientific
Advisory Team
BURGIN, Daniel, CEO        
YANG, Ching-Hong, CSO, Ph.D.     Chair Chair
CHEN, Xin, Ph.D.          
Hong, David   Chair Chair   Chair      
HUANG, Johnny, Ph.D.        
YANG, David   Chair      
SU, Wen-Pin, MD, Ph.D.              
DOWN, Greg, Ph.D.              
STAFFORD, Douglas, Ph.D.              
SUNDIN, George, Ph.D.